$ARVN in 29.35 Cypher Looking for 32+ (tp1) 1.2% risk, stop below X
May add with price action will share if I do
−6.50USD
−367.30 MUSD
78.50 MUSD
58.38 M
About Arvinas, Inc.
Sector
Industry
CEO
John G. Houston
Website
Headquarters
New Haven
Employees (FY)
445
Founded
2013
ISIN
US04335A1051
FIGI
BBG00LW7YK82
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Buy ARVN 8/9/2021Stock above EXMA 200 and still in uptrend
Stock is making higher low
EXMA 13 is equal EXMA 34
So you can buy target 105.3 stop loss 81.98
Good luck
ARVINAS STOCK PRICE SHOWING SOME STRENGTHOne of the stocks that came on my scan this week is ARVN. Gapped-Up December 2020 and has since pullback to value zone. Technically, looking prepared to move up again to re-test its January Swing High, however, another earning report is due 17 days time (Earnings may be dynamic and has nothing to do
Arvinas Nearly Doubles on Promising Cancer Drug ResultsArvinas Nearly Doubles on Promising Cancer Drug Results
The test results show the Arvinas drugs' potential for treating breast and prostate cancer, Cantor said.
Arvinas (ARVN) - Get Report shares blasted off Monday as Cantor Fitzgerald offered bullish comments on the biopharmaceutical company aft
ARVINAS INCAfter breaking the level of (36) with power . the market did a little pullback. but he was weak. at the moment there is a big probability that he will go around (20)
ARVN Short, purely speculative based on chartShort, purely speculative based on chart.
Seems to have a nice run to 2.816 Fib. that is plenty on couple of months. Target $28
Arvinas Pharmaceuticals likely to reach 25.60Arvinas Pharmaceuticals is on a run thanks to FDA approval of phase 1 clinical trials on a new drug. It's above critical resistance levels and appears to have clearance up to 25.60.
Personally I won't be taking a position in this one, though. Arvinas's earnings are pretty garbage, and honestly a ph
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ARVN is 34.64 USD — it has increased by 1.02% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arvinas, Inc. stocks are traded under the ticker ARVN.
Arvinas, Inc. is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
ARVN stock is 3.15% volatile and has beta coefficient of 2.63. Check out the list of the most volatile stocks — is Arvinas, Inc. there?
One year price forecast for Arvinas, Inc. has a max estimate of 110.00 USD and a min estimate of 49.00 USD.
ARVN earnings for the last quarter are −1.18 USD per share, whereas the estimation was −1.58 USD resulting in a 25.45% surprise. The estimated earnings for the next quarter are −1.19 USD per share. See more details about Arvinas, Inc. earnings.
Arvinas, Inc. revenue for the last quarter amounts to 34.60 M USD despite the estimated figure of 39.45 M USD. In the next quarter revenue is expected to reach 48.33 M USD.
Yes, you can track Arvinas, Inc. financials in yearly and quarterly reports right on TradingView.
ARVN stock has fallen by 6.10% compared to the previous week, the month change is a 18.36% fall, over the last year Arvinas, Inc. has showed a 27.31% increase.
ARVN net income for the last quarter is −154.80 M USD, while the quarter before that showed −64.00 M USD of net income which accounts for −141.88% change. Track more Arvinas, Inc. financial stats to get the full picture.
Today Arvinas, Inc. has the market capitalization of 2.33 B, it has decreased by 3.56% over the last week.
No, ARVN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ARVN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arvinas, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 445.00 employees. See our rating of the largest employees — is Arvinas, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arvinas, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arvinas, Inc. stock shows the sell signal. See more of Arvinas, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Arvinas, Inc. future price: according to them, ARVN price has a max estimate of 110.00 USD and a min estimate of 49.00 USD. Read a more detailed Arvinas, Inc. forecast: see what analysts think of Arvinas, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arvinas, Inc. EBITDA is −394.80 M USD, and current EBITDA margin is −502.93%. See more stats in Arvinas, Inc. financial statements.